Annamaria Vincenzi

Dr. Annamaria Vincenzi

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2025 in Cancers
Verified
Journal Article
Open access
PDF file
NPNovella Pugliese
Novella Pugliese
Marco PicardiMarco Picardi
Marco Picardi
CGClaudia Giordano
Claudia Giordano
AVAnnamaria Vincenzi
Annamaria Vincenzi
RCRosaria Cappiello
Rosaria Cappiello
FPFabrizio Pane
Fabrizio Pane
Background/Objectives: Lymph node (LN) evaluation is critical in diagnosing, staging, and managing various diseases, particularly lymphoma and metastatic cancer. Although conventional ultrasound (US) is widely used for this purpose, its limitations in reliably differentiating between benign and malignant LNs persist. Ultrasound elastography (US-E), which evaluates tissue stiffness, has emerged as a promising adjunct to improve diagnostic accuracy. This study aims to evaluate the diagnostic performance of conventional US, power Doppler US, and strain elastography (SE) in distinguishing malignant from benign superficial lymph nodes. Methods: In this prospective study, 214 consecutive patients referred for US of enlarged LNs were enrolled. Conventional B-mode US, power Doppler, and SE were performed, and the strain ratio (SR) was calculated as a measure of LN stiffness. Histopathological examination was used as the reference standard. Diagnostic accuracy was assessed using receiver operating characteristic (ROC) analysis, and multivariable logistic regression models were applied to determine the independent predictive role of SR. Results: Among the 214 LNs (one for each patient), 74 (34.6%) were benign and 140 (65.4%) were malignant. The SR showed a significant association with malignancy (p < 0.001). For hematological malignancies, SR demonstrated high sensitivity (79–85%) and specificity (81–96%), with an overall area under the curve (AUC) of 0.91. Multivariable analysis confirmed that SR was an independent predictor of malignancy (continuous and dichotomous), with a 14% gain in predictive accuracy when treated as a continuous variable (p < 0.0001). Conclusions: US-E, particularly SR, is a valuable tool in the differentiation of benign and malignant superficial LNs. SR provides significant diagnostic value, especially in hematological neoplasms like Hodgkin lymphoma, and can serve as an independent predictor of malignancy. This technique, when used in combination with conventional US features, offers enhanced diagnostic performance for LN evaluation.

6 November 2025 in European Journal of Haematology
Verified
Journal Article
Open access
MPMarco Picardi
Marco Picardi
AVAnnamaria Vincenzi
Annamaria Vincenzi
CGClaudia Giordano
Claudia Giordano
NPNovella Pugliese
Novella Pugliese
ASAlessia Scarpa
Alessia Scarpa
FPFabrizio Pane
Fabrizio Pane
BV + AVD is increasingly used for frontline treatment of stage III/IV cHL. Young adults and adults (Ya&A) were the most common patients treated with BV + AVD in clinical trials but have not been studied in non‐trial settings. We conducted a real‐life study in secondary and tertiary cancer centers to evaluate the PFS in 18–59 years aged patients who were scheduled to receive six BV + AVD for newly diagnosed advanced stage cHL. This is the largest cohort of Ya&A reported to date including 150 patients from four clinical institutions in Southern Italy, all of which employed structured supportive care programs for HL. Fifty patients (30%) had at least one ECHELON‐1 ineligibility criterion, including comorbidities and/or adverse performance status. All 150 patients underwent BV + AVD with a median relative dose intensity of 100% (dose reduction and/or discontinuation ≥ 15%, in 11% of them). At end‐of‐treatment (EoT) FDG‐PET, 93% (140/147) of patients (three did not undergo EoT FDG‐PET due to early grade 5 toxicity) achieved a complete response (95% CI, 88.1–96.8). Altogether, four patients (2.7%) received consolidation radiotherapy of residual nodal masses with a Deauville score of 4. Grade ≥ 2 peripheral neuropathy, cardiotoxicity, and febrile neutropenia were reported by 13%, 7%, and 3% of patients, respectively. With a 24 month median follow‐up, PFS in the entire analyzed population was 91% (95% CI, 0.864–0.958). In Ya&A with high‐risk cHL, our data suggest that a BV‐driven strategy (without bleomycin and consolidation radiotherapy) is an effective up‐front option in oncologic centers specialized in HL care, improving the rate of durable complete remission in routine clinical practice. Trial Registration: ClinicalTrials.gov identifier: NCT06857500

3 December 2025 in British Journal of Haematology
Verified
Journal Article
Open access
Marco PicardiMarco Picardi
Marco Picardi
AVAnnamaria Vincenzi
Annamaria Vincenzi
NPNovella Pugliese
Novella Pugliese
CGClaudia Giordano
Claudia Giordano
Massimo MascoloMassimo Mascolo
Massimo Mascolo
FPFabrizio Pane
Fabrizio Pane


14 November 2025 in HemaSphere
Verified
Journal Article
Open access
MPMarco Picardi
Marco Picardi
CGClaudia Giordano
Claudia Giordano
AVAnnamaria Vincenzi
Annamaria Vincenzi
ASAlessia Scarpa
Alessia Scarpa
NPNovella Pugliese
Novella Pugliese
FPFabrizio Pane
Fabrizio Pane

17 October 2025 in HemaSphere
Verified
Journal Article
Open access
MPMarco Picardi
Marco Picardi
AVAnnamaria Vincenzi
Annamaria Vincenzi
NPNovella Pugliese
Novella Pugliese
CGClaudia Giordano
Claudia Giordano
MPMaria Prastaro
Maria Prastaro
FPFabrizio Pane
Fabrizio Pane